Patients with type 2 diabetes and established cardiovascular disease may face a lower risk of major adverse cardiovascular events (MACE) when treated with the drug tirzepatide, according to a new analysis published in The BMJ. Researchers sought to fill a gap in the literature by comparing the effects of the medication against the current standard of care, using a large pool of real-world data to draw their conclusions.
The study examined 52,971 patients over the age of 40 who had type 2 diabetes and atherosclerotic cardiovascular disease. The group was divided into two main sections: one receiving tirzepatide and the other receiving sitagliptin, a placebo proxy known to have no documented cardiovascular effects.
By monitoring these patients for a year, the team tracked MACE, which includes myocardial infarction, stroke, and all-cause mortality. The results showed that the risk of MACE was 2.9% in the tirzepatide group compared to 4.4% in the sitagliptin group. This difference represents a 32% reduction in risk between the two groups.
Related: CAR-T Therapy Targets Glioblastoma
When looking at individual components of the main outcome, the data showed a specific trend. Tirzepatide treatment was associated with a lower hazard for myocardial infarction, whereas ischemic stroke showed no meaningful difference compared to the control group.
Broader Health Implications
Beyond the primary cardiovascular outcomes, the study noted that patients in the tirzepatide group required fewer hospitalizations for infections and had lower infection-related mortality. This suggests the medication might offer benefits that extend beyond heart health, though the specific mechanisms behind this remain unclear.
It is difficult to isolate the exact impact of the drug when patients are managing complex health needs. For a patient living with both diabetes and heart disease, the addition of a new medication can complicate daily management. The added benefits of lower infection rates could be a significant factor in the overall quality of life for these individuals, offering a reprieve from the frequent hospital visits that often accompany chronic illness management.
The researchers relied on an approach benchmarked against randomized trials to assess tirzepatide’s effectiveness. While this method provides a strong framework for comparison, the study authors acknowledged that residual confounding from unmeasured factors could partially explain the reduced risk of all-cause mortality.
Related: Astrin Targets Mainstream Proteomics With Breast Cancer Test
Commenting on the findings, a related editorial pointed out that the results are subtle. The authors noted that the reduction in risk depends substantially on how the outcome is defined. While the signal for myocardial infarction is clear, the data regarding stroke did not show a significant benefit.
Another consideration is the background treatment of the patients. Clinicians typically treat patients with cardiovascular disease using a combination of medications. The editorial noted that 21% of the patients were also treated with SGLT-2 inhibitors, which were not fully accounted for in the study’s primary analysis. Despite this, post hoc analysis still indicated a net positive effect of tirzepatide.
The study authors concluded that this research demonstrates how trial-anchored evidence from clinical practice can estimate the expected cardiovascular benefit of initiating tirzepatide beyond standard background treatment. They argued that the findings inform shared decision making while the authors of the editorial agreed that the signal is compelling, though the causal and clinical placement questions remain open.
Leave a Reply